Pharmaceuticals, Biotechnology and Life Sciences
SHANGHAI & FOSTER CITY, Calif.–(BUSINESS WIRE)–MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial…
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc. (CSE: SPR) (OTCQB:…
$46 Million Series A Round Co-led by ARCH Venture Partners and City Hill Ventures Company is Developing a Novel Class…
Tumor Reduction Demonstrated in Vivo Using Two Linear DNA Vaccines in Animal Models STONY BROOK, N.Y.–(BUSINESS WIRE)–$apdn #cancer—Applied DNA Sciences…
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological…
Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer.
Transgene has posted net loss amounted to €15.3 million for the first half of 2019 compared to €14.9 million for the same period in 2018, while its cash, cash equivalents and other financial assets amounted to €12.8 million versus €16.9 million as of December 31, 2018.
NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.
Onxeo said it stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin, with reaching satisfactory tolerance allowing the continuation of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers.
Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)